Want to see IN:CAPLIPOINT full AI Analyst Report?
Top Page
Caplin Point Laboratories Limited
(CAPLIPOINT)
Select Model
Select Model
Rating:81Outperform
Price Target:
₹3,031.00
▲(64.20% Upside)
Action:Reiterated
Date:07/01/26
The score is driven primarily by strong financial performance (robust profitability, ultra-low leverage, and solid cash generation) and supported by a clear technical uptrend. These positives are moderated by a relatively high P/E and a low dividend yield.
Positive Factors
Consistent Revenue Growth
Sustained revenue growth indicates durable demand for the company’s generic formulations and effective execution across domestic and export markets. Continued portfolio expansion and established distribution channels can support ongoing scale and recurring product sales.
Negative Factors
Uneven Free Cash Flow Conversion
Although operating cash flow is positive and improving, inconsistent conversion from earnings to free cash flow suggests working-capital or investment swings. This can reduce the predictability of funds available for expansion, acquisitions or shareholder returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent Revenue Growth
Sustained revenue growth indicates durable demand for the company’s generic formulations and effective execution across domestic and export markets. Continued portfolio expansion and established distribution channels can support ongoing scale and recurring product sales.
Read all positive factors
Caplin Point Laboratories Limited (CAPLIPOINT) vs. iShares MSCI India ETF (INDA)
Market Cap
₹193.23B
Dividend Yield0.28%
Average Volume (3M)3.75K
Price to Earnings (P/E)28.8
Beta (1Y)1.31
Revenue Growth15.01%
EPS Growth17.73%
CountryIN
Employees3,406
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)84.36
Shares Outstanding76,011,696
10 Day Avg. Volume2,866
30 Day Avg. Volume3,752
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)3.19
Price to Sales (P/S)5.23
P/FCF Ratio33.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)97
Revenue Forecast (FY)₹25.01B
Caplin Point Laboratories Limited Business Overview & Revenue Model
Company Description
Caplin Point Laboratories Limited is a pharmaceutical firm actively involved in the development, manufacture, marketing, and export of both generic medications and proprietary branded products, primarily operating within India. Their extensive pro...
How the Company Makes Money
Caplin Point makes money primarily by selling pharmaceutical formulations (finished-dose generics) in domestic and international markets. Its key revenue streams include: (1) product sales of its own branded and/or unbranded generic formulations t...
Caplin Point Laboratories Limited Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
96
Very Positive
Cash Flow
83
Very Positive
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 21.87B | 19.40B | 16.96B | 14.68B | 12.71B |
| Gross Profit | 10.50B | 11.38B | 9.40B | 7.89B | 6.99B |
| EBITDA | 8.76B | 6.49B | 5.51B | 4.40B | 3.94B |
| Net Income | 6.41B | 5.36B | 4.57B | 3.76B | 3.00B |
Balance Sheet | |||||
| Total Assets | 40.45B | 32.09B | 26.98B | 21.91B | 17.36B |
| Cash, Cash Equivalents and Short-Term Investments | 10.07B | 9.03B | 7.88B | 6.50B | 5.13B |
| Total Debt | 46.10M | 50.20M | 19.70M | 54.80M | 21.30M |
| Total Liabilities | 4.15B | 3.22B | 3.51B | 2.84B | 2.26B |
| Stockholders Equity | 35.86B | 28.50B | 23.16B | 18.80B | 14.84B |
Cash Flow | |||||
| Free Cash Flow | 3.37B | 2.41B | 1.73B | 779.00M | 2.46B |
| Operating Cash Flow | 5.85B | 4.32B | 3.18B | 2.72B | 3.37B |
| Investing Cash Flow | -6.45B | -3.35B | -3.20B | -2.18B | -3.77B |
| Financing Cash Flow | -455.90M | -383.20M | -380.70M | -281.70M | -407.10M |
Caplin Point Laboratories Limited Technical Analysis
Neutral
1845.95
Price Trends
2557.49
Negative
2247.08
Positive
2021.00
Positive
Market Momentum
-4.20
Positive
48.65
Neutral
52.40
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:CAPLIPOINT, the sentiment is Neutral. The current price of 1845.95 is below the 20-day moving average (MA) of 2539.66, below the 50-day MA of 2557.49, and below the 200-day MA of 2021.00, indicating a neutral trend. The MACD of -4.20 indicates Positive momentum. The RSI at 48.65 is Neutral, neither overbought nor oversold. The STOCH value of 52.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:CAPLIPOINT.
Caplin Point Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹193.23B | 28.76 | ― | 0.31% | 15.01% | 17.73% | |
79 Outperform | ₹119.83B | 40.56 | ― | 0.44% | 9.18% | -14.57% | |
67 Neutral | ₹90.56B | 15.32 | ― | 0.39% | 7.28% | 68.82% | |
64 Neutral | ₹206.30B | 30.92 | ― | 0.18% | 24.83% | 36.88% | |
58 Neutral | ₹286.11B | -92.27 | ― | 0.08% | 0.78% | -420.81% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
50 Neutral | ₹139.98B | 39.69 | ― | 0.52% | 16.27% | -23.50% |
* General Sector Average
IN:CAPLIPOINT
Caplin Point Laboratories Limited
2,516.10
421.86
20.14%
IN:AKUMS
Akums Drugs and Pharmaceuticals Limited
772.50
320.04
70.73%
IN:GRANULES
Granules India Limited
836.95
346.02
70.48%
IN:JUBLPHARMA
Jubilant Pharmova Limited
882.05
-132.15
-13.03%
IN:PPLPHARMA
Piramal Pharma Limited
218.60
35.00
19.06%
IN:STAR
Strides Pharma Science Ltd
1,020.55
161.32
18.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.